Paper33010331
Designing intelligent nano-bomb with on-demand site-specific drug burst release to synergize with high-intensity focused ultrasound cancer ablation.
Mai X and 4 others. J Control Release, 2021. Cited by 40 papers, by iCite.
Cite this record
ConductScience Library. Designing intelligent nano-bomb with on-demand site-specific drug burst release to synergize with high-intensity focused ultrasound cancer ablation. Papers, record 33010331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33010331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Designing intelligent nano-bomb with on-demand site-specific drug burst release to synergize with high-intensity focused ultrasound cancer ablation.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| High-Intensity Focused Ultrasound Ablation | Major topic |
| Neoplasms | Major topic |
| Pharmaceutical Preparations | Major topic |
| Humans | |
| Magnetic Resonance Imaging | |
| Silicon Dioxide |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42199658 | Nanoplatforms-Enhanced High-Intensity Focused Ultrasound for Cancer Immunotherapy. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42199658 | PubMed |
| 41426324 | Nanoparticle-ultrasound synergy: an emerging theranostic paradigm for breast and gynecologic cancers. | Front Oncol | 2025 | https://conductscience.org/library/papers/41426324 | PubMed |
| 41222383 | Spectral and Acoustic Characterization of Nanoenergetic Devices Based on Sodium Perchlorate-Impregnated Porous Silicon. | Nanomaterials (Basel) | 2025 | https://conductscience.org/library/papers/41222383 | PubMed |
| 40698150 | High intensity forced ultrasound-driven ferroptosis as a strategy for anti-tumor immune priming. | Acta Pharm Sin B | 2025 | https://conductscience.org/library/papers/40698150 | PubMed |
| 40503053 | CeO2 nanozyme-embedded thermal-deformative polymer for site-specific chemotherapy via HIF-1α-P-gp/lipolysis axis reversal. | Asian J Pharm Sci | 2025 | https://conductscience.org/library/papers/40503053 | PubMed |
| 40305624 | Biomimetic elasticity compressed assembly controls rapid intracerebral drug release to reverse microglial dysfunction. | Sci Adv | 2025 | https://conductscience.org/library/papers/40305624 | PubMed |
| 40040822 | Harnessing stimuli-responsive biomaterials for advanced biomedical applications. | Exploration (Beijing) | 2025 | https://conductscience.org/library/papers/40040822 | PubMed |
| 39385196 | US/PA/MR multimodal imaging-guided multifunctional genetically engineered bio-targeted synergistic agent for tumor therapy. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/39385196 | PubMed |
| 39150483 | Intertumoral and intratumoral barriers as approaches for drug delivery and theranostics to solid tumors using stimuli-responsive materials. | Mikrochim Acta | 2024 | https://conductscience.org/library/papers/39150483 | PubMed |
| 38659328 | Application of high intensity focused ultrasound combined with nanomaterials in anti-tumor therapy. | Drug Deliv | 2024 | https://conductscience.org/library/papers/38659328 | PubMed |
| 37803412 | Nanomaterial-Enabled Photothermal Heating and Its Use for Cancer Therapy via Localized Hyperthermia. | Small | 2024 | https://conductscience.org/library/papers/37803412 | PubMed |
| 37636983 | Lipid-hybrid cell-derived biomimetic functional materials: A state-of-the-art multifunctional weapon against tumors. | Mater Today Bio | 2023 | https://conductscience.org/library/papers/37636983 | PubMed |
| 37242696 | Nanoplatforms Potentiated Ablation-Immune Synergistic Therapy through Improving Local Control and Suppressing Recurrent Metastasis. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37242696 | PubMed |
| 37180717 | Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37180717 | PubMed |
| 37120558 | Dual mode imaging guided multi-functional bio-targeted oxygen production probes for tumor therapy. | J Nanobiotechnology | 2023 | https://conductscience.org/library/papers/37120558 | PubMed |
| 36650023 | Novel combination strategy of high intensity focused ultrasound (HIFU) and checkpoint blockade boosted by bioinspired and oxygen-supplied nanoprobe for multimodal imaging-guided cancer therapy. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/36650023 | PubMed |
| 35890217 | Stimuli-Responsive Gold Nanocages for Cancer Diagnosis and Treatment. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35890217 | PubMed |
| 35300712 | Ultrasound and nanomaterial: an efficient pair to fight cancer. | J Nanobiotechnology | 2022 | https://conductscience.org/library/papers/35300712 | PubMed |
| 35027950 | Aspects of high-performance and bio-acceptable magnetic nanoparticles for biomedical application. | Asian J Pharm Sci | 2021 | https://conductscience.org/library/papers/35027950 | PubMed |
| 35004614 | RNA Hydrogel Combined with MnO2 Nanoparticles as a Nano-Vaccine to Treat Triple Negative Breast Cancer. | Front Chem | 2021 | https://conductscience.org/library/papers/35004614 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33010331
GET https://conductscience.org/api/papers/v1/33010331/cited_by?page=2